Paracetamol/Codeïnefosfaat Accord Healthcare

Active Ingredient:: Paracetamol, Codeine Phosphate Hemihydrate
Origin:: EU

Paracetamol/Codeïnefosfaat Accord Healthcare (Paracetamol, Codeine Phosphate Hemihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Paracetamol, the active ingredient in Paracetamol/Codeïnefosfaat Accord Healthcare, is an analgesic combination presented as a tablet for oral use. It treats mild to moderate pain and reduces fever in adults and children when appropriate. GNH India supplies Paracetamol/Codeïnefosfaat Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paracetamol/Codeïnefosfaat Accord Healthcare is provided by GNH India, a licensed, GDP‑compliant supplier to hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Accord Healthcare B.V.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Paracetamol/Codeine Phosphate Hemihydrate is used for pain relief in several common conditions where moderate analgesia is required.

Dental pain: provides effective relief of postoperative dental discomfort.
Musculoskeletal pain: reduces pain associated with strains, sprains and low‑back pain.
Headache and migraine: alleviates moderate intensity headache episodes.
Post‑operative pain: helps control pain after minor surgical procedures.
Fever: lowers elevated body temperature associated with infection or inflammation.

How It Works

Paracetamol acts centrally to inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis and lowering the pain‑threshold. Codeine phosphate hemihydrate is an opioid agonist that binds to µ‑opioid receptors in the central nervous system, producing analgesia and a mild antitussive effect. The combination provides additive pain relief through complementary mechanisms.

Side Effects

Paracetamol/Codeine Phosphate Hemihydrate may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

Nausea: mild to moderate stomach upset.
Constipation: reduced bowel movements.
Drowsiness: feeling of sleepiness or reduced alertness.
Dizziness: light‑headed sensation.
Dry mouth: reduced salivary flow.

Serious or Rare Side Effects

Respiratory depression: slowed breathing, especially at higher doses.
Hepatotoxicity: liver injury from excessive paracetamol exposure.
Allergic reactions: rash, itching, swelling or anaphylaxis.
Dependence or misuse: potential for opioid‑related dependence with prolonged use.
Seizures: rare occurrence, particularly in overdose situations.

Precautions & Warnings

When prescribing Paracetamol/Codeine Phosphate Hemihydrate, clinicians should consider several safety aspects.

Liver function: avoid use in patients with severe hepatic impairment.
Respiratory conditions: use cautiously in asthma or chronic obstructive pulmonary disease.
Opioid sensitivity: assess risk of dependence in patients with a history of substance abuse.
Pregnancy and lactation: limit use to situations where benefits outweigh risks.
Concomitant CNS depressants: monitor for enhanced sedation.
Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Paracetamol/Codeine Phosphate Hemihydrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may reduce codeine conversion to active metabolite.
CNS depressants (e.g., benzodiazepines, alcohol): increase risk of respiratory depression.
MAO inhibitors: heightened risk of serotonin syndrome when combined with codeine.

Moderate Interactions (Monitor Closely)

Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
Anticholinergic agents: may worsen constipation.
Diuretics: potential for reduced renal clearance of paracetamol.

Frequently Asked Questions

Paracetamol/Codeïnefosfaat Accord Healthcare is an oral analgesic combination used to relieve moderate pain such as dental, musculoskeletal, postoperative or headache pain, and to reduce fever when a stronger effect than paracetamol alone is required.

Paracetamol reduces pain by inhibiting central cyclooxygenase enzymes, lowering prostaglandin production. Codeine binds to µ‑opioid receptors in the brain and spinal cord, providing additional analgesia and a mild cough‑suppression effect. Together they give additive pain relief.

The prescribed dose of Paracetamol/Codeine is individualized by a healthcare professional based on the patient’s age, weight, pain severity and clinical condition. The prescriber determines the appropriate strength, frequency and duration of therapy.

Paracetamol/Codeine should only be used in pregnancy or while breastfeeding when the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers usually limit use to short‑term treatment and consider alternative analgesics when possible.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with paracetamol alone, the addition of codeine provides stronger analgesia for moderate pain but introduces opioid‑related risks such as dependence and respiratory depression. It is less potent than stronger opioids like morphine, offering a balance between efficacy and safety for many outpatient settings.

Store the tablets below 25 °C in their original container, protecting them from moisture, heat and direct sunlight. Do not use the product after the expiry date printed on the packaging.

The medication is taken orally, usually with a glass of water. It may be taken with or without food, but taking it with food can reduce stomach upset. Patients should follow the dosing instructions provided by their prescriber.

Serious risks include respiratory depression, especially in opioid‑naïve individuals or when combined with other depressants, and liver injury from excessive paracetamol exposure. Allergic reactions and potential dependence with prolonged use are also important safety concerns.

Individuals with severe hepatic impairment, known hypersensitivity to paracetamol or codeine, significant respiratory disorders, or a history of opioid dependence should avoid this medication. It is also contraindicated in children under the age limits set by local regulatory authorities.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.